Congratulation to Jacob and Vincent for there work on the synthesis of TD139, a galectin inhibitor clinical candidate for the treatment of idiopathic pulmonary fibrosis. This publication publication follows the filling of a US Provisional patent (USPTO 62/861,476).
UNIVERSITÉ LAVAL | FACULTÉ DES SCIENCES ET GÉNIES | DÉPARTEMENT DE CHIMIE
- - -
© Groupe Giguère | Chimie organique de synthèse et chimie médicinale | Synthetic organic and medicinal chemistry
Design : Ublo.ca